A number of investment brokers have recently updated their price targets on shares of Aquinox Pharmaceuticals, Inc. (AQXP). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/16/2016 – Aquinox Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 21 price target on the stock.

03/15/2016 – Aquinox Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 9 price target on the stock.

11/11/2015 – Aquinox Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 25 price target on the stock.

11/03/2015 – Aquinox Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 23 price target on the stock.

10/08/2015 – Aquinox Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 22 price target on the stock.

10/06/2015 – Guggenheim began new coverage on Aquinox Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 22 price target on the stock.

05/02/2015 – Aquinox Pharmaceuticals, Inc. was upgraded to “hold” by analysts at Zacks.

The share price of Aquinox Pharmaceuticals, Inc. (AQXP) was down -5.99% during the last day of trading, with a day high of 8.16. 240041 shares were traded during the last session.

The stock’s 50 day moving average is 9.04 and its 200 day moving average is 10.80. The stock’s market capitalization is 132.35M. Aquinox Pharmaceuticals, Inc. has a 52-week low of 1.38 and a 52-week high of 55.75.

View other investors thoughts on Aquinox Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.